Subscription is FREE for qualified healthcare professionals in the US.
Subscribe or renew to PPM

All Headache Articles

Biohaven, Lilly, and Allergan's new research from the American Headache Society (AHS) meeting.
Headache expert Lawrence Robbins, MD, asks a series of questions clinicians need to address before prescribing the long-awaited CGRP antagonists for migraine prevention.
In this exclusive roundtable, developers recap the data on their CGRP inhibitors, including Aimovig, the first-ever monoclonal antibodies specifically designed to prevent chronic or episodic migraine.
In  this exclusive roundtable, Amgen/Novartis, Allergan, Lilly, and Teva recap the data that is moving their CGRP migraine preventives to the finish line. Introduction to CGRPs by Lawrence Robbins, MD
Men with chronic migraine have been shown to be at a high risk of sleep apnea and other disorders.
Amgen, Novartis, Alder, Allergan, BioHaven, Lilly, and Teva are all anticipating FDA approval of their novel anti-CGRP chronic migraine preventive medications in 2018
CGRP receptor antagonists have been well tolerated in studies.
Findings challenge a 2006 FDA advisory, questioning its validity
Lilly survey results point to need for new headache and migraine treatments as well as patient education.
Diagnosing medication overuse headache, versus medication overuse, can be a tough task for practitioners. Here's how to differentiate the two.
While migraines are an acute pain issue for many, promising results for ubrogepant are encouraging.
Two New Pain Relief Stimulators May Alleviate Chronic Pain from Cluster Headaches & Migraines
Device from Cefaly Technology promises to abort migraines more effectively than triptans.
A patient’s perception of stress appears to offer a good forecast factor to predict the onset of episodic migraines.
Three case studies and a review of current practice guidelines offer insight into treating patients with chronic pain and other symptoms after a sport-related concussion.